2019 International Congress

Monday, September 23, 2019

1:45pm-3:15pm

Botulinum toxin type A therapy in a movement disorders unit: a 23-year experience.

M. Velez, C. Cosentino, L. Torres (Lima, Peru)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease

W. Poewe, K. Kieburtz, F. Stocchi, S. Oren, T. Yardeni, L. Adar, O. Rosenfeld, C. Olanow (Innsbruck, Austria)

Clinical Trials, Pharmacology and Treatment  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Brain and spinal cord structural alterations in non-ataxic and ataxic SCA3 mutation carriers

J. Faber, I. Giordano, B. Koyak, R. Wolz, S. Romanzetti, MC. Franca Jr, H. Jiang, A. Durr, B. Bender, J. Diedrichsen, T. Klockgether (Bonn, Germany)

Ataxia  ·  Les Muses, Level 3

1:45pm-3:15pm

Brain MRI Volume Changes after 12 months laquinimod treatment of Huntington disease (LEGATO-HD)

R. Reilmann, M. Gordon, A. Feigin, K. Anderson, S. Tabrizi, B. Leavitt, J. Stout, P. Piccini, N. Hobbs, R. Manber, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Victoria, Australia)

Huntington’s Disease  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Brain MRI-based discrimination between multiple system atrophy type cerebellar from other late onset sporadic cerebellar ataxias: a prospective study with implications for diagnosis criteria

G. Carré, JL. Dietemann, O. Gebus, S. Montaut, O. Lagha-Boukbiza, T. Wirth, S. Kremer, IJ. Namer, M. Anheim, C. Tranchant (Strasbourg, France)

Ataxia  ·  Les Muses, Level 3

1:45pm-3:15pm

Burden of Huntington’s disease in the US: Analysis of an insured population

K. Raimundo, J. Luo, R. Tan, T. To, R. Fuller, J. Warner (South San Francisco, CA, USA)

Huntington’s Disease  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Can a smartphone accelerometer differentiate between functional and organic tremor ?

M. Khider Ahmed, T. Mouton, J. Ackerman, N. Brey, C. Albertyn, F. Henning, J. Carr (Cape Town, South Africa)

Functional (Psychogenic) Movement Disorders  ·  Les Muses Terrace, Level 3

1:45pm-3:15pm

Can people with Parkinson’s disease rely on their coping capacity over time? A longitudinal study using the Sense of Coherence (SOC) scale

J. Andersson, G-M. Hariz, L. Forsgren (Umeå, Sweden)

Other  ·  Agora 2 West, Level 2

1:45pm-3:15pm

Can we hear pathology in premanifest Huntington’s disease? Acoustic and listener-based analysis of speech

J. Chan, C. Shirbin, J. Stout, A. Vogel (Melbourne, Australia)

Huntington’s Disease  ·  Agora 3 West, Level 3

1:45pm-3:15pm

Cardiac involvement in AVED

S. Lucas-Delpozo, D. Moreno-Martínez, M. Tejero-Ambrosio, J. Hernández-Vara (Barcelona, Spain)

Ataxia  ·  Les Muses, Level 3